[A22-80] Trastuzumab deruxtecan (breast cancer) – Benefit assessment according to §35a Social Code Book V
Last updated 03.02.2023
Project no.:
A22-80
Commission:
Commission awarded on 29.07.2022 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Patients with unresectable or metastatic HER2-positive breast cancer who have previously received HER2-targeted therapy
- Patients < 65 years: hint of considerable added benefit
- Patients ≥ 65 years: added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A22-81 | Trastuzumab deruxtecan (breast cancer, HER2+, at least 2 prior therapies) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A22-126 | Trastuzumab deruxtecan (breast cancer, after 1 prior therapy) – Addendum to Commission A22-80 | Commission completed |
| A23-07 | Trastuzumab deruxtecan (breast cancer) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A23-115 | Trastuzumab deruxtecan (NSCLC) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A23-08 | Trastuzumab deruxtecan (gastric cancer) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2023-02-02 A G-BA decision was published.